These developments will also require (a) GMP compliant technologies to mass produce stem cells, and (b) testing platforms that mimic human pathophysiology (e.g., 3D bioprinted organoids, organ-on-chip) to allow high-throughput screening and rapid testing of stem cells safety and efficacy.